venclexta 10 mg tablets
abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 10 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphomavenclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemiavenclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.
venclexta 100 mg tablets
abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 100 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphomavenclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemiavenclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.
venclexta 50 mg tablets
abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 50 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphomavenclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemiavenclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.
rubraca 200 mg
neopharm ltd, israel - rucaparib as camsylate - film coated tablets - rucaparib as camsylate 200 mg - rucaparib - for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube,or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
rubraca 250 mg
neopharm ltd, israel - rucaparib as camsylate - film coated tablets - rucaparib as camsylate 250 mg - rucaparib - for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube,or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
rubraca 300 mg
neopharm ltd, israel - rucaparib as camsylate - film coated tablets - rucaparib as camsylate 300 mg - rucaparib - for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube,or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
venclexta 10 mg film-coated tablet
abbvie inc. - venetoclax - film-coated tablet - 10 mg
venclexta 50 mg film-coated tablet
abbvie inc. - venetoclax - film-coated tablet - 50 mg
venclexta 100 mg film-coated tablet
abbvie inc., united states - venetoclax - film-coated tablet - 100 mg
venclexta 10 mg / 50 mg / 100 mg film-coated tablet
abbvie inc., united states - venetoclax - film-coated tablet - 10, 50, 100 mg